Therapeutic gene transfer to dystrophic diaphragm by an adenoviral vector deleted of all viral genes

Stefan Matecki,1 Roy W. R. Dudley,1 Maziar Divangahi,1 Renald Gilbert,2,3 Josephine Nalbantoglu,2 George Karpati,2 and Basil J. Petrof1,2

1Meakins-Christie Laboratories and Respiratory Division, McGill University Health Center, McGill University, Montréal H3A 1A1; 2Neuromuscular Research Group, Montréal Neurological Institute, McGill University, Montréal H3A 2B4; and 3Biotechnology Research Institute, National Research Council of Canada, Montréal, Québec, Canada H4P 2R2

Submitted 29 March 2004 ; accepted in final form 13 May 2004


    ABSTRACT
 TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Duchenne muscular dystrophy is caused by defects in the dystrophin gene, and the mdx mouse is the most frequently employed genetic model of this disease. It is well known that different muscle groups do not respond in the same way to dystrophin deficiency. In particular, the mdx mouse diaphragm exhibits severe morphological and functional changes not found in other mdx muscles. Use of early generation adenoviral vectors to deliver genes to the diaphragm in immunocompetent mdx mice has been associated with substantial functional toxicity and a rapid loss of transgene expression. Here we determined the response to dystrophin gene replacement in the mdx diaphragm using a "gutted" adenoviral vector that contains the coding sequence of two full-length dystrophin genes and is deleted of most viral DNA sequences. At 1 wk postdelivery of the vector, 23.6 ± 4% of total fibers in the injected diaphragm bundle expressed dystrophin at the sarcolemma, which remained stable over the study duration of 30 days without the need for continuous immunosuppression. Treated diaphragms showed a significantly improved resistance to the abnormal force deficits induced by high-stress muscle contractions, the latter being a functional hallmark of dystrophin-deficient muscle. This functional amelioration was achieved despite the presence of mildly increased inflammation (CD4+ and CD8+ lymphocytes) within the vector-treated diaphragms. To our knowledge, this is the first demonstration that a viral vector can achieve reversal of functional abnormalities in the dystrophic diaphragm via therapeutic dystrophin gene transfer without the need for sustained immunosuppressive therapy.

Duchenne muscular dystrophy; gene therapy; dystrophin deficiency; viral vectors; mdx mouse


DUCHENNE MUSCULAR DYSTROPHY (DMD) is the most common fatal X-linked recessive disorder in humans, affecting ~1 in 3,500 live male births. The disease is caused by genetic mutations of the dystrophin gene (16), which encodes a large (427-kDa) cytoskeletal protein normally found on the cytoplasmic surface of the muscle cell membrane, or sarcolemma. The characteristic muscle pathology found in DMD patients consists of myofiber necrosis with ensuing muscle fiber loss, fibrosis, and fatty cell infiltration. This leads to progressive weakness of all skeletal muscles, including the diaphragm and other respiratory muscles. Consequently, ventilatory insufficiency is a central problem in the management of DMD patients, and most patients will die in their late teens or early twenties unless supported by mechanical ventilation (41).

Because of a lack of effective therapeutic options, DMD has been considered a prime candidate for cell or gene therapy, the goal of which is to transfer normal copies of the dystrophin gene into the muscle fibers of affected patients. To be clinically feasible, two essential features of such an intervention in patients are 1) an appropriate dystrophin gene construct, expressed at adequate levels to achieve improvements in muscle function, and 2) a lack of significant vector toxicity. To address these requirements, newer generation AdV, also referred to as helper-dependent or "gutted" vectors, have been developed. A murine model of DMD, the mdx mouse, also lacks dystrophin due to a nonsense point mutation in exon 23 of the dystrophin gene (40). We (11) and others (8, 12) have recently reported that gutted AdV are able to achieve sustained dystrophin gene expression in adult mdx mice without the need for concomitant host immunosuppression.

All studies to date that have employed gutted AdV to achieve therapeutic dystrophin gene transfer in mdx mice have limited their evaluation to the hindlimb musculature (5, 8, 11, 12, 15). However, it is important to recognize that different skeletal muscle groups do not respond in the same way to dystrophin deficiency. For example, extraocular muscles in mdx mice and humans are spared from clinical disease (38). Furthermore, hindlimb muscles of mdx mice show only mild fibrosis or functional alteration until late in life (22, 31, 43). On the other hand, the mdx mouse diaphragm exhibits major fibrosis and myofiber loss as well as greatly impaired contractile function from an early age (35, 43). Interestingly, it has also been reported that the effects of tumor necrosis factor-{alpha} gene inactivation on mdx diaphragm and quadriceps pathology are diametrically opposed (42). The precise reasons for these muscle-specific divergences in the response to dystrophin deficiency are not well understood. However, the findings are consistent with recently published data suggesting that responses of a particular muscle to a lack of dystrophin are likely determined by unique aspects of its underlying constitutive gene expression profile (37, 38).

In view of the above observations, it is evident that the response of dystrophin-deficient muscles to gene therapy may also be governed by muscle group-specific factors. Therefore, although dystrophin gene transfer with gutted AdV has been shown to be beneficial in mdx mouse hindlimb muscles, this cannot automatically be assumed to be the case for other skeletal muscle groups. In the case of the diaphragm in particular, this issue is of major importance for at least two reasons. First, there is a much greater phenotypic resemblance between human DMD muscles and the mdx diaphragm when compared with any other mdx muscle (43). Second, targeting of the respiratory muscles will ultimately be required to prolong the lifespan of DMD patients, since respiratory insufficiency is the most frequent cause of death. Accordingly, the primary objectives of the present study were 1) to evaluate the physiological efficacy of full-length dystrophin gene transfer to the mdx mouse diaphragm using a gutted AdV deleted of all viral genes, and 2) to assess the cellular immune response to AdV-mediated dystrophin gene transfer as well as its relationship to the stability of dystrophin expression in the mdx diaphragm under these conditions.


    MATERIALS AND METHODS
 TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
HDCBDysM Construction and Growth

The gutted AdV used in these experiments, henceforth referred to as HDCBDysM, has been previously described in detail (11). The construct contains two full-length murine dystrophin cDNAs, both regulated by a hybrid cytomegalovirus enhancer/chicken {beta}-actin promoter that is highly active in adult skeletal muscle (18). The vector was propagated using the 293Cre-loxP system (30) and purified by two consecutive CsCl gradient centrifugations. The CsCl was removed from the viral preparation by chromatography on Sephadex G25 columns (Amersham Pharmacia Biotech, Piscataway, NJ), and HDCBDysM was eluted with freezing buffer (50 mM HEPES, pH 7.5, 2 mM MgCl2, 150 mM NaCl, 5% sucrose). The viral titer was determined by measuring the optical density at 260 nm (25), and HDCBDysM DNA structure was confirmed by Southern blot analysis. The level of contamination by E1/E3-deleted helper adenovirus ranged between 0.02 and 0.17%, as determined by measuring the cytopathic effect after infection of 293A cells (28).

Animal Procedures

All aspects of the study were approved by the institutional animal ethics committee. Dystrophin-deficient mdx mice and wild-type C57BL10 mice were purchased from The Jackson Laboratory (Bar Harbor, ME). The mice (12 wk old) were anesthetized with ketamine (130 mg/kg) and xylazine (20 mg/kg) by intramuscular (im) injection. A laparotomy was performed to reveal the abdominal surface of the diaphragm. With the aid of a dissecting microscope, the mdx diaphragm was directly injected with AdV as previously described in detail (32). The mdx mice received injections of HDCBDysM (5 x 1010 vector particles, diluted in 100 µl of saline) into the hemidiaphragm on one side, whereas the contralateral side was injected with saline alone to serve as a within-animal control. To blunt any acute toxic inflammatory reaction to viral capsid proteins contained in the HDCBDysM inoculating dose (47), methylprednisolone was also given (2.5 mg·kg–1·day–1 im) for 3 days before and 2 days after vector administration. We have previously shown that this dose of methylprednisolone has no significant effects on the contractile properties of the mdx diaphragm (46). Animals recovered well from the surgery and demonstrated no untoward effects. The mice were killed at either 7 or 30 days after HDCBDysM administration.

Measurement of Diaphragmatic Contractility Parameters

Isometric contractile properties. At 30 days postinjection, mice were anesthetized (130 mg/kg im ketamine and 20 mg/kg im xylazine) to achieve a loss of deep pain reflexes. HDCBDysM-treated and untreated mdx diaphragm strips were then carefully removed in random order to determine in vitro isometric contractile properties as previously described in detail (45). Briefly, the diaphragm strips were mounted vertically in a jacketed tissue bath chamber filled with Ringer solution continuously perfused with 95% O2:5% CO2 and maintained at 27°C (pH 7.4). The costal margin of each diaphragm strip was securely anchored to a platform near the base of the chamber while the central tendon was tied to the lever arm of a force transducer/length servomotor system (model 300B dual mode; Cambridge Technology, Watertown, MA). A mobile micrometer stage (Newport Instruments, Toronto, Canada) was employed to allow incremental adjustments of muscle length. Electrical field stimulation was induced via platinum plate electrodes placed into the bath on both sides of the muscle. Supramaximal stimuli with monophasic pulse duration of 2 ms were delivered using a computer-controlled electrical stimulator (model S44; Grass Instruments, Quincy, MA) connected in series to a power amplifier (model 6824A; Hewlett Packard, Palo Alto, CA). Muscle force was displayed on a storage oscilloscope (Tektronix, Beaverton, OR), and the data were simultaneously acquired to computer (Labdat/Anadat software; RHT-InfoData, Montreal, Quebec, Canada) via an analog-to-digital converter at a sampling rate of 1,000 Hz for later analysis. After adjusting each muscle strip to optimal length (Lo, the length at which maximal twitch force is achieved), we sequentially stimulated the muscles at low (10 Hz) and high (100 Hz) frequencies for 300 ms each, with a 2-min recovery period between each contraction; this allowed the spectrum of isometric tetanic force at the two ends of the force-frequency relationship to be ascertained. Diaphragm strips were then removed from the bath, and Lo was directly measured under a dissecting microscope with microcalipers accurate to 0.1 mm. Total muscle strip cross-sectional area was determined by dividing muscle weight by its length and tissue density (1.056 g/cm3). This allowed specific force (force/cross-sectional area) to be calculated, which was expressed as N/cm2.

Resistance to contraction-induced mechanical stress. Muscle fibers lacking in dystrophin are abnormally susceptible to damage triggered by the high mechanical stresses associated with eccentric (i.e., lengthening) muscle contractions (34). Therefore, we subjected diaphragm strips to eccentric contractions and determined the resulting force deficit, which was defined as the percent decline in isometric force from the first to the last eccentric contraction. The latter served as a functional indicator of contraction-induced mechanical injury to dystrophic muscle as previously reported (7, 34). Each contraction involved supramaximal stimulation at 100 Hz for a total of 300 ms; the muscle was held at Lo during the initial 100 ms (isometric component) and then lengthened through a distance of 15% of Lo during the last 200 ms (eccentric component). Peak muscle length was maintained for an additional 100 ms after the cessation of electrical stimulation, followed by a return to Lo during the next 100 ms. A total of five such contractions were imposed on the muscle strip, each being separated by a 30-s recovery period. Last, a 100-Hz stimulation was performed at Lo to determine the final level of isometric force production at the end of the eccentric contraction protocol. Because the damage and isometric force deficit associated with eccentric contractions are directly correlated with the peak mechanical stress placed on the muscle (34), the force deficit was normalized to peak muscle stress as previously described (10, 11). All measurements were performed on HDCBDysM-treated and untreated diaphragm strips of mdx mice as well as in untreated diaphragm strips obtained from wild-type C57BL10 mice of the same age.

Immunohistochemistry and Morphometric Analysis

After completing the muscle function studies, we embedded diaphragms in mounting medium and snap-froze them in isopentane precooled with liquid nitrogen. Transverse sections (6-µm-thick) were obtained in a cryostat and then fixed on slides in 1% acetone.

Dystrophin. Immunohistochemical procedures were carried out to detect dystrophin expression using a polyclonal antidystrophin (COOH terminus) primary antibody and biotinylated secondary antibody (45), with subsequent visualization by either horseradish peroxidase- or Cy3-conjugated streptavidin (Jackson ImmunoResearch Laboratories, West Grove, PA). Microscopically visualized sections were photographed using a digital camera, and the image was stored on computer. Analysis of the number and cross-sectional area of dystrophin-positive and dystrophin-negative myofibers on the entire diaphragm muscle strip cross section (averaging ~800 myofibers) was then performed using image analysis software (ImagePro Plus; Media Cybernetics, Silver Spring, MD).

T lymphocytes. The cellular immune response to HDCBDysM injection of the mdx diaphragm was evaluated after 30 days by staining consecutive cryostat sections for CD4+ or CD8+ T lymphocytes as previously described (33). After anti-mouse CD4 (L3T4; BD Biosciences Pharmingen, Mississauga, Ontario, Canada) and CD8a (Ly2; Cedarlane, Hornby, Ontario, Canada) monoclonal antibodies raised in rat were applied, the sections were rinsed and reacted with appropriate biotinylated secondary antibodies (Jackson ImmunoResearch Laboratories). Specific staining was then visualized using the avidin-biotin peroxidase detection system (Vectastain ABC; Vector Labs, Burlingame, CA). For each muscle analyzed, computer-assisted image analysis (ImagePro Plus) was employed to determine the number of positively staining T lymphocytes in transduced areas. This was done by placing a rectangular grid encompassing ~400 myofibers over the epicenter of the transduced area on the computer image; the number of CD4+ or CD8+ T lymphocytes was then determined and expressed per 100 myofibers (transduced as well as nontransduced) contained within the grid area.

Statistical Analysis

All data are expressed as mean values ± SE. Data were analyzed using one- or two-way ANOVA, with post hoc application of Dunn's method where appropriate (SigmaStat; SPSS, Chicago, IL). Statistical significance was set at P < 0.05.


    RESULTS
 TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Stability of Dystrophin Expression in mdx Diaphragms After HDCBDysM Administration

After HDCBDysM injection of the mdx diaphragm, dystrophin-expressing fibers were found to be present in a somewhat nonuniform pattern of distribution throughout the muscle strip, as shown in Fig. 1. By immunohistochemistry, most dystrophin-expressing fibers demonstrated circumferential sarcolemmal staining for dystrophin at both 7 and 30 days post-HDCBDysM injection. In some instances, cytoplasmic staining was also observed, indicating that the level of dystrophin expression within these transduced fibers exceeded normal physiological levels. As expected, there was also a very small number of dystrophin-expressing fibers in the untreated mdx diaphragm, which are known to represent somatic cell mutations or so-called "revertant" fibers (17) that do not offer significant functional protection against the dystrophic process (9).



View larger version (75K):
[in this window]
[in a new window]
 
Fig. 1. Dystrophin expression after treatment of adult mdx diaphragm with gutted helper-dependent vector (HDCBDysM). A: representative cryostat section of mdx diaphragm immunostained for dystrophin at 30 days after HDCBDysM administration. Note circumferential sarcolemmal staining and, in some cases, cytoplasmic immunoreactivity for dystrophin. B: contralateral saline-injected (untreated) mdx diaphragm immunostained for dystrophin at the same time point.

 
In HDCBDysM-treated mdx diaphragms, dystrophin expression was stable over the time course of the study. Hence, there was no significant change in the number of dystrophin-expressing fibers in the diaphragm between 7 and 30 days after HDCBDysM injection (see Fig. 2A). The relative contribution of dystrophin-expressing muscle fibers to total diaphragm muscle strip cross-sectional area was also determined (see Fig. 2B). This was found to comprise 20–25% of the total muscle area, and there was no significant alteration in the percentage of the diaphragmatic muscle area demonstrating dystrophin expression between the two time points examined.



View larger version (16K):
[in this window]
[in a new window]
 
Fig. 2. Quantification of dystrophin-expressing fibers in mdx diaphragms after HDCBDysM administration. For each excised diaphragm strip, the data are expressed in terms of the absolute number of dystrophin-expressing fibers (A) or the percentage of dystrophin-expressing fibers (B). All values are means ± SE, n = number of muscles analyzed. *P < 0.001 compared with the untreated contralateral diaphragm.

 
Cellular Immune Response in mdx Diaphragms After HDCBDysM Administration

Transduced areas of the diaphragm injected 30 days earlier with HDCBDysM were immunostained for markers of CD8+ and CD4+ T lymphocytes, which play a central role in the immune-mediated loss of transgene expression after AdV-mediated gene transfer to muscle (33, 47). As shown in Figs. 3 and 4, there was a significant increase in the number of infiltrating T cells within the HDCBDysM-injected regions of the mdx diaphragm. There was a tendency for CD4+ T cells to outnumber the CD8+ T lymphocytes in the HDCBDysM-injected muscles, but this did not achieve statistical significance. It was hypothesized that the magnitude of the inflammatory response could be directly related to the number of transduced fibers if the latter represent an ongoing antigenic stimulus; alternatively, inflammatory cells could be responsible for the destruction of transduced fibers, in which case an inverse correlation would be expected. However, there was no significant correlation (either positive or inverse) between the number of dystrophin-expressing fibers in HDCBDysM-treated diaphragms and the levels of CD4+ or CD8+ lymphocytic infiltration.



View larger version (119K):
[in this window]
[in a new window]
 
Fig. 3. T lymphocyte infiltration of the diaphragm 30 days after treatment with HDCBDysM. Representative cryostat sections immunostained for CD4+ T cells (A) and CD8+ T cells (B) are shown. The untreated contralateral diaphragm was also immunostained for CD4+ (C) and CD8+ (D) cells.

 


View larger version (16K):
[in this window]
[in a new window]
 
Fig. 4. Quantification of the number CD4+ and CD8+ T lymphocytes. Both CD4+ and CD8+ T cells are increased above baseline values at 30 days after HDCBDysM administration. All values are means ± SE, n = number of muscles analyzed. *P < 0.001 compared with the untreated contralateral diaphragm.

 
Physiological Function of mdx Diaphragms After Full-Length Dystrophin Gene Transfer with HDCBDysM

At 1 mo after vector administration, there were no significant effects of HDCBDysM on either maximal twitch (2.9 ± 0.3 vs. 2.9 ± 0.4 N/cm2 during 1-Hz stimulation in treated and untreated, respectively), submaximal tetanic (4.6 ± 1.1 vs. 4.4 ± 0.5 N/cm2 during 10-Hz stimulation in treated and untreated, respectively), or maximal tetanic (10.1 ± 0.6 vs. 9.0 ± 0.9 N/cm2 during 100-Hz stimulation in treated and untreated, respectively) force production by the mdx diaphragm. Because a characteristic feature of dystrophin-deficient muscle is an abnormal susceptibility to injury caused by mechanical stress (34), we next determined the magnitude of the force deficits induced by imposing a series of eccentric contractions on the diaphragm. As shown in Fig. 5, there was a significant protective effect of HDCBDysM against eccentric contraction-induced force deficits. Hence, the force deficits induced by such high mechanical stress contractions were significantly lower in the HDCBDysM-treated mdx diaphragm strip compared with the untreated mdx muscle. It should be noted, however, that the protection afforded by HDCBDysM was not sufficient to completely normalize the response, as values in the HDCBDysM-treated mdx diaphragm remained intermediate between those seen in untreated mdx diaphragm strips and normal wild-type mice.



View larger version (20K):
[in this window]
[in a new window]
 
Fig. 5. HDCBDysM treatment of adult mdx diaphragm improves the resistance to contraction-induced injury. The force deficit induced by a series of high-stress eccentric contractions is significantly greater in untreated mdx diaphragm strips than in mdx diaphragm strips injected 1 mo earlier with HDCBDysM.

 

    DISCUSSION
 TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Different skeletal muscles do not necessarily respond identically to a lack of dystrophin, and this is equally true for potential therapeutic interventions for dystrophin deficiency. Indeed, we previously found that diaphragm and hindlimb (soleus) muscles of mdx mice exhibited different responses after being injected with first-generation AdV containing a 6.3-kb dystrophin minigene; the latter produced physiological improvements in the mdx hindlimb muscle but not in the diaphragm (45). Recently, gene expression profiling with oligonucleotide microarrays has revealed striking differences in the transcriptome between diaphragm and hindlimb muscles of normal as well as mdx mice (37). The majority of these differentially transcribed genes cannot be attributed to known fiber type differences. In fact, the differences between diaphragm and hindlimb (37) are substantially greater than between prototypical fast- and slow-twitch hindlimb muscles (1). Furthermore, the transcriptional pattern observed in diaphragm suggests a higher presence of antigen-presenting cells and other immune-responsive elements (37), suggesting at least one possible basis for the less favorable response to dystrophin gene transfer using first-generation AdV in the mdx diaphragm (45).

In the absence of dystrophin, muscle fibers are abnormally susceptible to contraction-induced tears of the muscle cell membrane, or sarcolemma (6, 34). Sarcolemmal damage may have several adverse consequences for muscle fibers, including depressed contractility and strength (34, 44), increased calcium influx into the muscle cells (24), and cellular necrosis. Because the mdx diaphragm is a physiologically relevant preclinical model for testing therapeutic interventions for DMD (43), we sought to evaluate the effects of full-length dystrophin gene transfer to the diaphragm in immunocompetent mdx mice using a fully gutted adenoviral vector. The major findings of our study were 1) full-length dystrophin gene transfer to the mdx diaphragm by HDCBDysM provided significant protection against the exaggerated loss of contractile force induced by high-stress muscle contractions in dystrophin-deficient muscles (34), and 2) despite mild T lymphocyte infiltration of the muscle, dystrophin expression in the mdx diaphragm was stable over a 30-day period without the need for continuous immunosuppressive therapy.

Physiological Effects of Gutted AdV in mdx Diaphragm

One of the most characteristic physiological findings in dystrophin-deficient muscles is an exaggerated loss of force-generating capacity after being subjected to high-stress eccentric contractions (7, 34). To our knowledge, this is the first report that dystrophin gene transfer with any viral vector can achieve functional benefits in the diaphragm with respect to this major hallmark of dystrophin deficiency. The magnitude of the effect was similar to that found after injection of the same vector into mdx hindlimb muscle (11). On the other hand, there was no significant difference in the nonstressed isometric force-generating capacity between untreated and AdV-treated diaphragms over the time course of our study.

Our findings are consistent with those recently reported by DelloRusso et al. (8) as well as Gilbert et al. (11) in adult mdx hindlimb muscles treated with gutted AdV encoding dystrophin. Therefore, our results and those of previous studies (7, 8, 11) indicate that a decreased vulnerability to the injurious effects of eccentric contractions is a sensitive marker of the early physiological efficacy of dystrophin gene replacement in mdx muscles. This is consistent with dystrophin's putative role as a cytoskeletal protein that provides mechanical reinforcement to the muscle cell but is not directly involved in the process of force generation. Hence, dystrophin replacement is not expected to acutely restore normal muscle strength but only to prevent or slow the process of further disease progression. It is likely that to demonstrate beneficial effects on isometric force production in muscles with established dystrophic pathology such as the mdx diaphragm, it would be necessary to observe the effects of treatment over a period of several months. Studies performed in transgenic mdx mice expressing dystrophin cDNAs have shown that dystrophin expression at ~20% of wild-type levels is sufficient to prevent the myopathic phenotype (36). However, this differs from the situation in the current investigation, since in our study we treated mdx diaphragms postnatally at a time when substantial pathology and functional impairment were already present. In addition, it is possible that the percentage of transduced muscle fibers needed to ameliorate isometric force production under these conditions is greater than the level required to decrease force deficits caused by eccentric contractions.

We have previously demonstrated that in the absence of continuous immunosuppression, injection of first-generation AdV into the mdx diaphragm causes a profound decrease in the isometric force-generating capacity of the muscle (32). Under these conditions, both CD8+ and CD4+ T lymphocytes appear to play a role in the loss of force production by the diaphragm (33). In addition, leaky expression of viral gene products has a direct toxic effect on diaphragmatic muscle fibers, independent of cell-mediated immunity, which further compromises diaphragmatic contractility (33). Therefore, although dystrophin gene transfer with our gutted AdV did not improve isometric force-generating capacity of the diaphragm within the time frame examined in this study, it is important to note that adverse effects on isometric force previously observed after the use of first-generation AdV (32, 33) did not occur. This suggests that the margin of safety associated with treatment by gutted AdV is substantially greater than with first-generation vectors that still contain adenoviral genes.

The HDCBDysM vector employed in our study is deleted of all viral sequences except for the inverted terminal repeats and packaging signal (11). Because this vector cannot express viral gene products, both T cell-mediated destruction of transduced fibers and direct toxic effects on myofibers should be greatly mitigated. In addition, the increased cloning capacity of gutted AdV allows for use of the full-length dystrophin transgene, which is functionally superior to truncated forms of the gene used in other viral vectors (36). Indeed, the greatly increased insert capacity of our gutted AdV in particular (36 kb as opposed to ~8 kb with earlier generation AdV) permitted delivery of not only one but two full-length dystrophin cDNAs per vector particle. In principle, this should allow one to achieve a higher level of therapeutic dystrophin gene delivery for a given inoculating dose, thereby further reducing any dose-dependent toxic or immune-mediated adverse effects on muscle function.

Cellular Immune Response to Gutted AdV in mdx Diaphragm

Without immunosuppressive therapy, transgene expression mediated by first-generation AdV is almost completely eliminated within 3–4 wk due to T cell-mediated destruction of the transduced cells (47, 48). In contrast, gutted AdV achieved sustained transgene expression in nondystrophic skeletal muscles without evidence of inflammation (2, 3). Several groups have reported similarly encouraging results with the use of gutted AdV in other models (20, 23, 26, 27, 39, 49). Although HDCBDysM was clearly superior to first-generation AdV (45) in its ability to avoid immune-mediated loss of transduced fibers in the mdx diaphragm, increased T lymphocyte infiltration of the diaphragm was nonetheless observed. Possible sources of this cellular immune response to HDCBDysM in the diaphragm include 1) the low-level contamination of the HDCBDysM preparation by nongutted helper virus (estimated as being 0.02–0.17%), which could not be completely eliminated with the available purification methods, 2) an immune reaction against murine dystrophin itself, since the latter may be treated as a neoantigen by the dystrophin-deficient host (12, 14, 29), and 3) a response to the viral capsid proteins contained in the initial AdV inoculum (19), even though the latter are more often associated with humoral rather than cellular adaptive immunity (47). Although T lymphocyte infiltration of the diaphragm was not associated with any reduction in dystrophin-expressing fibers or force-generating capacity in our study, previous work in adult mdx hindlimb muscles showed a gradual decrease in dystrophin expression several months after administration of HDCBDysM (11). Longer-term studies will be needed to determine whether this is also the case in the diaphragm.

In conclusion, we have found that full-length dystrophin gene transfer to the mdx diaphragm with a gutted adenoviral vector can achieve significant physiological reversal of a characteristic hallmark of dystrophic muscular dysfunction. In addition, stable dystrophin transgene expression was achieved in the mdx diaphragm over a 1-mo period, without apparent toxicity or a need for continuous immunosuppressive therapy. To the extent that the mdx diaphragm is a severely affected muscle that is phenotypically similar to human DMD, these findings suggest that gutted AdV may be a promising system for therapeutic gene transfer in this disease. However, a number of issues must be addressed before this can be considered. In particular, a more efficient delivery method is needed that will permit more widespread gene transfer within the diaphragm and other respiratory muscles. Although direct injection of the diaphragm could conceivably be performed via minimally invasive surgery (e.g., laparoscopy), it would be preferable to target a larger percentage of muscle fibers through the vascular system. This will likely be required to have a clinically significant positive impact on respiratory muscle strength. Recently, several investigators have made progress toward this goal (4, 13, 21). Finally, it will be important to identify the principal source of residual immune responsiveness to HDCBDysM or other gutted AdV and to determine whether a low but clinically acceptable level of immunosuppressive therapy is needed to sustain physiologically effective levels of dystrophin expression in the diaphragm over a period of many months or years.


    GRANTS
 TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
This investigation was supported by grants from the Canadian Institutes for Health Research, the Muscular Dystrophy Associations of USA and Canada, and the Association Francaise Contre les Myopathies.


    ACKNOWLEDGMENTS
 
S. Matecki received a Postdoctoral Fellowship from the Canadian Institutes of Health Research. J. Nalbantoglu is a National Research Scholar of the Fonds de la recherche en sante du Quebec and a Killam Scholar. G. Karpati holds a Killam Chair of Neurology from the Montréal Neurological Institute. B. J. Petrof is a National Research Scholar of the Fonds de la recherche en sante du Quebec.


    FOOTNOTES
 

Address for reprint requests and other correspondence: B. J. Petrof, Respiratory Division, Rm. L411, Royal Victoria Hospital, 687 Pine Ave. W., Montréal, Québec, Canada H3A 1A1 (E-mail: basil.petrof{at}mcgill.ca)

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.


    REFERENCES
 TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 

  1. Campbell WG, Gordon SE, Carlson CJ, Pattison JS, Hamilton MT, and Booth FW. Differential global gene expression in red and white skeletal muscle. Am J Physiol Cell Physiol 280: C763–C768, 2001.[Abstract/Free Full Text]
  2. Chen HH, Mack LM, Choi SY, Ontell M, Kochanek S, and Clemens PR. DNA from both high-capacity and first-generation adenoviral vectors remains intact in skeletal muscle. Hum Gene Ther 10: 365–373, 1999.[CrossRef][ISI][Medline]
  3. Chen HH, Mack LM, Kelly R, Ontell M, Kochanek S, and Clemens PR. Persistence in muscle of an adenoviral vector that lacks all viral genes. Proc Natl Acad Sci USA 94: 1645–1650, 1999.
  4. Cho WK, Ebihara S, Nalbantoglu J, Gilbert R, Massie B, Holland P, Karpati G, and Petrof BJ. Modulation of Starling forces and muscle fiber maturity permits adenovirus-mediated gene transfer to adult dystrophic (mdx) mice by the intravascular route. Hum Gene Ther 11: 701–714, 2000.[CrossRef][ISI][Medline]
  5. Clemens PR, Kochanek S, Sunada Y, Chan S, Chen HH, Campbell KP, and Caskey CT. In vivo muscle gene transfer of full-length dystrophin with an adenoviral vector that lacks all viral genes. Gene Ther 3: 965–972, 1996.[ISI][Medline]
  6. Danialou G, Comtois AS, Dudley R, Karpati G, Vincent G, Des Rosiers C, and Petrof BJ. Dystrophin-deficient cardiomyocytes are abnormally vulnerable to mechanical stress-induced contractile failure and injury. FASEB J 15: 1655–1657, 2001.[Abstract/Free Full Text]
  7. Deconinck N, Ragot T, Marechal G, Perricaudet M, and Gillis JM. Functional protection of dystrophic mouse (mdx) muscles after adenovirus-mediated transfer of a dystrophin minigene. Proc Natl Acad Sci USA 93: 3570–3574, 1996.[Abstract/Free Full Text]
  8. DelloRusso C, Scott JM, Hartigan-O'Connor D, Salvatori G, Barjot C, Robinson AS, Crawford RW, Brooks SV, and Chamberlain JS. Functional correction of adult mdx mouse muscle using gutted adenoviral vectors expressing full-length dystrophin. Proc Natl Acad Sci USA 99: 12974–12984, 2002.
  9. Dunant P, Larochelle N, Thirion C, Stucka R, Ursu D, Petrof BJ, Wolf E, and Lochmuller H. Expression of dystrophin driven by the 1.35-kb MCK promoter ameliorates muscular dystrophy in fast, but not in slow muscles of transgenic mdx mice. Mol Ther 8: 80–89, 2003.[CrossRef][ISI][Medline]
  10. Ebihara S, Guibinga GH, Nalbantoglu J, Gilbert R, Massie B, Holland P, Karpati G, and Petrof BJ. Differential effects of dystrophin and utrophin gene transfer in immunocompetent muscular dystrophy (mdx) mice. Physiol Genomics 3: 133–144, 2000.[Abstract/Free Full Text]
  11. Gilbert R, Dudley RW, Liu AB, Petrof BJ, Nalbantoglu J, and Karpati G. Prolonged dystrophin expression and functional correction of mdx mouse muscle following gene transfer with a helper-dependent (gutted) adenovirus encoding murine dystrophin. Hum Mol Genet 12: 1287–1299, 2003.[Abstract/Free Full Text]
  12. Gilchrist SC, Ontell MP, Kochanek S, and Clemens PR. Immune response to full-length dystrophin delivered to Dmd muscle by a high-capacity adenoviral vector. Mol Ther 6: 359–368, 2002.[CrossRef][ISI][Medline]
  13. Greelish JP, Su CH, Lankford EB, Burkman JM, Chen H, Konig SK, Mercier IM, Desjardins PR, Mitchell MA, Zheng XG, Leferovich J, Gao GP, Balice-Gordon RJ, Wilson JM, and Stedman HH. Stable restoration of the sarcoglycan complex in dystrophic muscle perfused with histamine and a recombinant adeno-associated viral vector. Nat Med 5: 439–443, 1999.[CrossRef][ISI][Medline]
  14. Guibinga GH, Lochmüller H, Massie B, Nalbantoglu J, Karpati G, and Petrof BJ. Combinatorial blockade of calcineurin and CD28 signaling facilitates primary and secondary therapeutic gene transfer by adenovirus vectors in dystrophic (mdx) mouse muscles. J Virol 72: 4601–4609, 1998.[Abstract/Free Full Text]
  15. Haecker SE, Stedman HH, Balice-Gordon RJ, Smith DBJ, Greelish JP, Mitchell MA, Wells A, Sweeney HL, and Wilson JM. In vivo expression of full-length human dystrophin from adenoviral vectors deleted of all viral genes. Hum Gene Ther 7: 1907–1914, 1996.[ISI][Medline]
  16. Hoffman EP, Brown RHJ, and Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 51: 919–928, 1987.[ISI][Medline]
  17. Hoffman EP, Morgan JE, Watkins SC, and Partridge TA. Somatic reversion/suppression of the mouse mdx phenotype in vivo. J Neurol Sci 99: 9–25, 1990.[CrossRef][ISI][Medline]
  18. Ishii A, Hagiwara Y, Saito Y, Yamamoto K, Yuasa K, Sato Y, Arahata K, Shoji S, Nonaka I, Saito I, Nabeshima Y, and Takeda S. Effective adenovirus-mediated gene expression in adult murine skeletal muscle. Muscle Nerve 22: 592–599, 1999.[CrossRef][ISI][Medline]
  19. Kafri T, Morgan D, Krahl T, Sarvetnick N, Sherman L, and Verma I. Cellular immune response to adenoviral vector infected cells does not require de novo viral gene expression: implications for gene therapy. Proc Natl Acad Sci USA 95: 11377–11382, 1998.[Abstract/Free Full Text]
  20. Kim IH, Jozkowicz A, Piedra PA, Oka K, and Chan L. Lifetime correction of genetic deficiency in mice with a single injection of helper-dependent adenoviral vector. Proc Natl Acad Sci USA 98: 13282–13287, 2001.[Abstract/Free Full Text]
  21. Liu F, Nishikawa M, Clemens PR, and Huang L. Transfer of full-length Dmd to the diaphragm muscle of Dmd(mdx/mdx) mice through systemic administration of plasmid DNA. Mol Ther 4: 45–51, 2001.[CrossRef][ISI][Medline]
  22. Louboutin JP, Fichter-Gagnepain V, Thaon E, and Fardeau M. Morphometric analysis of mdx diaphragm muscle fibres. Comparison with hindlimb muscles. Neuromuscul Disord 3: 463–469, 1993.[CrossRef][Medline]
  23. Maione D, Wiznerowicz M, Delmastro P, Cortese R, Ciliberto G, La Monica N, and Savino R. Prolonged expression and effective readministration of erythropoietin delivered with a fully deleted adenoviral vector. Hum Gene Ther 11: 859–868, 2000.[CrossRef][ISI][Medline]
  24. McCarter GC and Steinhardt RA. Increased activity of calcium leak channels caused by proteolysis near sarcolemmal ruptures. J Membr Biol 176: 169–174, 2000.[CrossRef][ISI][Medline]
  25. Mittereder N, March KL, and Trapnell BC. Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J Virol 70: 7498–7509, 1996.[Abstract]
  26. Morral N, Parks RJ, Zhou H, Langston C, Schiedner G, Quinones J, Graham FL, Kochanek S, and Beaudet AL. High doses of a helper-dependent adenoviral vector yield supraphysiological levels of {alpha}1-antitrypsin with negligible toxicity. Hum Gene Ther 9: 2709–2716, 1998.[ISI][Medline]
  27. Morsy MA, Gu M, Motzel S, Zhao J, Lin J, Su Q, Allen H, Franlin L, Parks RJ, Graham FL, Kochanek S, Bett AJ, and Caskey CT. An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene. Proc Natl Acad Sci USA 95: 7866–7871, 1998.[Abstract/Free Full Text]
  28. Nyberg-Hoffman C, Shabram P, Li W, Giroux D, and Aguilar-Cordova E. Sensitivity and reproducibility in adenoviral infectious titer determination. Nat Med 3: 808–811, 1997.[ISI][Medline]
  29. Ohtsuka Y, Udaka K, Yamashiro Y, Yagita H, and Okumura K. Dystrophin acts as a transplantation rejection antigen in dystrophin-deficient mice: implication for gene therapy. J Immunol 160: 4635–4640, 1998.[Abstract/Free Full Text]
  30. Parks RJ, Chen L, Anton M, Sankar U, Rudnicki MA, and Graham FL. A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc Natl Acad Sci USA 93: 13565–13570, 1996.[Abstract/Free Full Text]
  31. Pastoret C and Sebille A. Mdx mice show progressive weakness and muscle deterioration with age. J Neurol Sci 129: 97–105, 1995.[CrossRef][ISI][Medline]
  32. Petrof BJ, Acsadi G, Jani A, Massie B, Bourdon J, Matusiewicz N, Yang L, Lochmuller H, and Karpati G. Efficiency and functional consequences of adenovirus-mediated in vivo gene transfer to normal and dystrophic (mdx) mouse diaphragm. Am J Respir Cell Mol Biol 13: 508–517, 1995.[Abstract]
  33. Petrof BJ, Lochmüller H, Massie B, Yang L, Macmillan C, Zhao JE, Nalbantoglu J, and Karpati G. Impairment of force generation after adenovirus-mediated gene transfer to muscle is alleviated by adenoviral gene inactivation and host CD8+ T cell deficiency. Hum Gene Ther 7: 1813–1826, 1996.[ISI][Medline]
  34. Petrof BJ, Shrager JB, Stedman HH, Kelly AM, and Sweeney HL. Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc Natl Acad Sci USA 90: 3710–3714, 1993.[Abstract]
  35. Petrof BJ, Stedman HH, Shrager JB, Eby J, Sweeney HL, and Kelly AM. Adaptations in myosin heavy chain expression and contractile function in the dystrophic (MDX) mouse diaphragm. Am J Physiol Cell Physiol 265: C834–C841, 1993.[Abstract/Free Full Text]
  36. Phelps SF, Hauser MA, Cole NM, Rafael JA, Hinkle RT, Faulkner JA, and Chamberlain JS. Expression of full-length and truncated dystrophin mini-genes in transgenic mdx mice. Hum Mol Genet 4: 1251–1258, 1995.[Abstract]
  37. Porter JD, Merriam AP, Leahy P, Gong B, Feuerman J, Cheng G, and Khanna S. Temporal gene expression profiling of dystrophin-deficient (mdx) mouse diaphragm identifies conserved and muscle group-specific mechanisms in the pathogenesis of muscular dystrophy. Hum Mol Genet 13: 257–269, 2004.[Abstract/Free Full Text]
  38. Porter JD, Merriam AP, Leahy P, Gong B, and Khanna S. Dissection of temporal gene expression signatures of affected and spared muscle groups in dystrophin-deficient (mdx) mice. Hum Mol Genet 12: 1813–1821, 2003.[Abstract/Free Full Text]
  39. Schiedner G, Morral N, Parks RJ, Wu Y, Koopmans SC, Langston C, Graham FL, Beaudet AL, and Kochanek S. Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nat Genet 18: 180–183, 1998.[CrossRef][ISI][Medline]
  40. Sicinski P, Geng Y, Ryder Cook AS, Barnard EA, Darlison MG, and Barnard PJ. The molecular basis of muscular dystrophy in the mdx mouse: a point mutation. Science 244: 1578–1580, 1989.[ISI][Medline]
  41. Smith PEM, Calverley PMA, Edwards RHT, Evans GA, and Campbell EJM. Practical problems in the respiratory care of patients with muscular dystrophy. N Engl J Med 316: 1197–1204, 1987.[ISI][Medline]
  42. Spencer MJ, Marino MW, and Winckler WM. Altered pathological progression of diaphragm and quadriceps muscle in TNF-deficient, dystrophin-deficient mice. Neuromuscul Disord 10: 612–619, 2000.[CrossRef][ISI][Medline]
  43. Stedman HH, Sweeney HL, Shrager JB, Maguire HC, Panettieri RA, Petrof B, Narusawa M, Leferovich JM, Sladky JT, and Kelly AM. The mdx mouse diaphragm reproduces the degenerative changes of Duchenne muscular dystrophy. Nature 352: 536–539, 1991.[CrossRef][ISI][Medline]
  44. Warren GL, Hayes DA, Lowe DA, and Armstrong RB. Mechanical factors in the initiation of eccentric contraction-induced injury in rat soleus muscle. J Physiol 464: 457–475, 1993.[Abstract]
  45. Yang L, Lochmüller H, Luo J, Massie B, Nalbantoglu J, Karpati G, and Petrof BJ. Adenovirus-mediated dystrophin minigene transfer improves muscle strength in adult dystrophic (mdx) mice. Gene Ther 5: 369–379, 1998.[CrossRef][ISI][Medline]
  46. Yang L, Luo J, and Petrof BJ. Corticosteroid therapy does not alter the threshold for contraction-induced injury in dystrophic (mdx) mouse diaphragm. Muscle Nerve 21: 394–397, 1998.[CrossRef][ISI][Medline]
  47. Yang Y, Haecker SE, Su Q, and Wilson JM. Immunology of gene therapy with adenoviral vectors in mouse skeletal muscle. Hum Mol Genet 5: 1703–1712, 1996.[Abstract/Free Full Text]
  48. Yang Y, Nunes FA, Berencsi K, Furth EE, Gonczol E, and Wilson JM. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 91: 4407–4411, 1994.[Abstract]
  49. Zou L, Zhou H, Pastore L, and Yang K. Prolonged transgene expression mediated by a helper-dependent adenoviral vector (hdAd) in the central nervous system. Mol Ther 2: 105–113, 2000.[CrossRef][ISI][Medline]